key: cord-0867149-to4hoeug
authors: Gioia, Magda; Ciaccio, Chiara; calligari, Paolo; De Simone, Giovanna; sbardella, Diego; tundo, Grazia; Francesco Fasciglione, Giovanni; di Masi, Alessandra; Di Pierro, Donato; Bocedi, Alessio; Ascenzi, Paolo; Coletta, Massimo
title: Role of Proteolytic Enzymes In the Covid-19 Infection And Promising Therapeutic Approaches
date: 2020-09-19
journal: Biochem Pharmacol
DOI: 10.1016/j.bcp.2020.114225
sha: eaea31878366c6ace133604d5ba59497ca8fd15a
doc_id: 867149
cord_uid: to4hoeug

In the Fall of 2019 a sudden and dramatic outbreak of a pulmonary disease (Coronavirus Disease COVID-19), due to a new Coronavirus strain (i.e., SARS-CoV2), emerged in the continental Chinese area of Wuhan and quickly diffused throughout the world, causing up to now several hundreds of thousand deaths. As for common viral infections, the crucial event for the viral life cycle is the entry of genetic material inside the host cell, realized by the spike protein of the virus through its binding to host receptors and its activation by host proteases; this is followed by translation of the viral RNA into a polyprotein, exploiting the host cell machinery. The production of individual mature viral proteins is pivotal for replication and release of new virions. Several proteolytic enzymes either of the host and of the virus act in a concerted fashion to regulate and coordinate specific steps of the viral replication and assembly, such as (i) the entry of the virus, (ii) the maturation of the polyprotein and (iii) the assembly of the secreted virions for further diffusion. Therefore, proteases involved in these three steps are important targets, envisaging that molecules which interfere with their activity are promising therapeutic compounds. In this review, we will survey what is known up to now on the role of specific proteolytic enzymes in these three steps and of most promising compounds designed to impair this vicious cycle.

Over the past twenty years, β-Coronaviruses (CoV)s have caused three epidemics/pandemics, namely SARS-CoV in 2002, MERS-CoV in 2013 and SARS-CoV-2 in 2019, which have been associated with acute severe respiratory illnesses. As of September 8, SARS-CoV-2 virus, responsible for the global COVID-19 pandemic, has been causing more than 27 millions of contagions and around 900.000 deaths worldwide (https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports). The scientific community has come together to understand the mechanisms underlying the infection and the virulence of SARS-CoV-2 virus, as well as all symptoms and risk factors for subsequent mortality). Currently, there is neither antiviral nor vaccine for the severe acute respiratory syndrome induced by SARS-CoV-2. Its alarming spread and its severity across most countries elicited an effort for the elucidation of the pathogenetic features of this novel viral infection in search for effective therapeutic approaches (Morse et al., 2020) .

Little is known about the pathobiology of SARS-CoV-2, even though the availability of the virus genome sequence (GenBank ID: MN908947.3) has demonstrated crucial similarities between SARS-CoV-2 and other members of the same viral order (i.e., Nidovirales) . Hence, to rapidly gain insights on molecular mechanism of SARS-CoV-2 it is worth exploiting what we have learned from several medicinal chemistry studies on viral spreading to help us in finding promising targets for the development of anti-viral strategies for SARS-CoV-2.

As for common viral infections, the crucial event for the viral life cycle is the entry of genetic , which encompasses about 75% of the viral genome, is translated into two viral replicase polyproteins (i.e., pp1a and pp1ab) ( Figure 1 ). Sixteen mature non-structural proteins (nsp) arise from further processing of these two pps, which are autocatalytically processed by two proteases (also autoprocessed), namely (a) the papain-like protease (PLpro), which cleaves the first two non-structural proteins (nsp1 and nsp2) at the N-terminal region of the polyprotein, and (b) the main protease (Mpro, also known as a chymotrypsin-like cysteine protease, 3CLpro), which recognizes cleavage sites at the C-terminus and brings to the production of about 11 individual mature non-structural proteins (Simmons et al., 2013; Bredenbeek et al., 1990; Lee et al., 1991) . The remaining ORFs encode accessory and structural proteins, like spike surface glycoprotein (S), small envelope protein (E), matrix protein (M), nucleocapsid protein (N) (see Fig. 1 ).

Since proteolytic enzymes are the major actors of the various events described in this review and although knowledge about their role is continuously expanding, it may be worth recalling that they can be roughly classified into seven broad groups (from the type of aminoacid involved as proton donor for the activation of the peptide bond to be cleaved), namely (a) serine protease, (b) cysteine protease, (c) threonine protease, (d) aspartic protease, (e) glutamic protease, (f) metalloproteases (usually employing Zn ++ ), and (g) asparagine peptide lyases (Barrett et al., 2004; Sbardella et al., 2012) . Within each group, a further differentiation can be applied according to whether the peptide bond cleaved by the specific enzyme corresponds to a terminal residue (i.e., exoprotease) or else to one of aminoacids within the sequence (i.e., endoprotease).

The activity of several endoproteases ensures viral infection, involving host and viral proteases which belong to the classes of serine-and cysteine-proteases, respectively. Both proteases of the host cell (which are supposed to assist the virus during the intracellular and extracellular phases of its cycle) and those of the virus act in a concerted fashion to regulate and coordinate specific steps of the viral propagation, such as (i) the entry and the replication of the virus, (ii) the maturation of the polyprotein and (iii) the assembly of the secreted virions for further diffusion (Simmons et al., 2013) (Figure 2 ).

The spike glycoproteins are responsible for the crown-like appearance of Coronavirus particles ( Figure 3A ), playing a crucial role for the entry of the viral genome inside the host cell (Fig.   2 ). The first critical step is the binding of the homotrimeric S protein with its specific cellular receptor, which triggers a cascade of proteolytic events leading to the fusion of cell and viral membranes.

Similarity in structure and sequence with SARS-CoV and in vitro binding measurements indicate that SARS-CoV-2 S protein shows an improved binding for the receptor of angiotensin converting enzyme2 (ACE2), identifying it as the main host receptor (Lan et al 2020) . The S protein is synthesized as an uncleaved precursor which includes two functionally distinct domains (i.e., S1 and S2 domains) that are responsible for receptor binding and triggering of the fusion event, respectively ( Figure 3B ).

The inactive CoV S protein acquires both cellular receptor binding and fusion function upon cleavage events at different sites, which can be carried out by multiple proteases at multiple sites in different cell compartments (Garten, 2018 , Hoffman et al 2018) (see Fig. 2 ). Importantly, depending on CoV strain and cell type, CoV S protein is activated at a specific cell localization by one or several host proteases, including furin, trypsin, cathepsin L, transmembrane protease serine protease2 (TMPRSS2), TMPRSS4, or human airway trypsin-like protease (HAT) (Ou et al 2020) (see Fig. 2 ).

Exploiting redundant pathways to activate surface glycoproteins, the activating cleavage is mediated by multiple host membrane proteases via two distinct pathways, namely either (i) the late endosomal pathway, using cathepsins, and/or (ii) the cell-surface or early endosome pathway, using transmembrane serine proteases (e.g., TMPRSS2 and pro-protein convertase furin) (Fig. 2 ).

It has been suggested that the surface route is preferred under natural conditions, while repeated passages in cultured cells in vitro appears to exert a selective pressure in favour of virions bearing a greater capacity to invade the target cell via late endosomes (Shirato et al 2018 , Hoffman et al 2018 , Coutard et al 2020 . Thus, to activate the fusion machinery of the viral S protein the cooperation in space and in time of multiple membrane proteases is demanded; the actually involved pool depends on both the virus strain and the specific host cell type expression profile of proteases (thus changing for each cell type).

Among host proteases, involved in the viral infection, furin is the one most widely present, being constitutively expressed in a variety of cell types. It cycles from the trans Golgi network (TGN)/endosomal compartments and cell surface, and it is known to accumulate in the TGN (where it is supposed to fulfil its proteolytic activity) (Thomas, 2002) (Fig. 2) . Nevertheless, recently it has been also detected linked to the membrane of oral and airway epithelial cells (Lin et al., 2020; Bestle et al., 2020) .

Unlike close relatives, SARS-CoV-2 can promptly infect a broad spectrum of human cell types, spanning from lung cells to endothelial, conjunctival and gut cells, with the respiratory district being the main target, displaying the peculiar ability to infect even the upper respiratory tract. The efficient spreading of virus relies on the protease arsenal of host cells which mediate the propagation of viral infection. The expression profile of furin and ACE2 in human cells could explain why SARS-CoV-2 is so efficient in spreading virus particles, since they are present throughout the body in endothelial cells with particularly increased levels in cells lying in alveoli and small intestine (Cyranoski 2020) . Moreover, SARS-CoV-2 S protein possesses a peculiar insertion of four amino acids (i.e., Ser-Pro-Arg -Arg-Ala-Arg689, see Zhou et al 2020a and Figure 3C ), which has been identified as an additional cleavage site for the specificity of furin activity, strengthening the idea that this enzyme plays a dominant relevance in SARS-CoV-2 viral infection. (Coutard et al 2020 , Hoffman et al., 2020a , Hoffman et al 2020b , Jaimes et al 2020a .

Therefore, furin may play either (a) a role in the first entry of the virus, thanks to its topological location at the outer membrane (which would allow the formation of the ternary complex with ACE2,

i.e., furin:SARS-CoV-2S:ACE2), and/or (b) during the transport of virions along the secretory pathway, further facilitating the virus diffusion (Fig. 2 ). This co-expression has been detected in airway epithelia, cardiac tissues and enteric canals (Lin et al., 2020) , envisaging the possibility that in these districts the role of furin in favouring the virus cell entry is relevant, providing a cellular and molecular basis for the comprehension of the major clinical effects of COVID-19 in the tissues where these cell types are located.

A key discovery in understanding the mechanism of SARS-CoV-2 infection concerns the role of the androgen-responsive transmembrane serine protease 2 (TMPRSS2), that is expressed by specific epithelial tissues (including those of the respiratory and digestive tracts), facilitating the SARS-CoV-2 entry in the human airways by cleaving the viral spike (S) protein (Lin et al., 1999; Jacquinet et al., 2001; Hoffmann et al., 2020a) (Fig. 2 ).

Beside host proteolytic enzymes, two viral proteases, namely Mpro and PLpro (involved in the maturation of viral polyprotein) are also recognized as important drug target(s). In particular, Mpro has been found to play a prominent role in the viral gene expression and replication, thus becoming an attractive target for anti-CoV-2 drugs. Notably, its quaternary structure renders Mpro ideal for rational drug design strategies against SARS-CoV-2, as there is a correlation between homodimer formation and the enzyme catalytic activity. Each protomer contains an antiparallel βbarrel structure, which has a folding scaffold similar to other viral chymotrypsin-like proteases.

However, unlike chymotrypsin, the active site of SARS-CoV-2 Mpro contains a catalytic cysteinyl residue instead of a serine residue.

It must be stressed that although the endoprotease classes shows a variety of catalytic sites (see above) and distinct protein folding, functional similarity can be found across evolutionary distant species (from viruses to humans) (Barrett et al., 2004) , thus representing a caveat in the development of effective COVID-19 therapeutic strategies.

Further, structural and evolutionary analyses indicate that SARS-CoV-2 Mpro is a highly conserved viral protein, which recognizes the sequence Leu-Met-Phe-GlnSer-Gly-Ala while no human proteases share the same specificity (Hilgenfeld, 2014) . This unique feature makes Mpro an even more attractive target for a broad inhibition of multiple stages in the viral life cycle (such as viral formation, progression of the viral infection and reproduction of virions).

Overall, two very attractive processes (which indeed represent important targets for designing anti-viral drugs), will be discussed here: (a) the proteolytic activation of the S protein (by furin and TMPRRS2), impairing the entry of viral genetic material inside the host cell, and (b) the activity of viral proteases (in particular Mpro), impairing the formation of mature viral proteins, which are required for the progression of the viral infection and replication of viruses.

Multiple cleavages of coronavirus S protein are the primary determinants of the viral tropism, since this protein is responsible for receptor binding and, once cleaved, it drives the fusion of the viral envelope with the cell membrane.

This large glycoprotein (approx. 180 kDa) is present on the viral surface as a prominent trimer, each monomer ectodomain being composed of S1 and S2 domains (Fig. 3B ). Although the sequence comparison of the S protein between SARS-CoV and SARS-CoV-2 indicates only 76% identity (large variations exist at the N-terminus), it has been assumed that their folding is similar (Walls et al 2020) .

The approx. 1200 amino acid sequence of the spike glycoprotein consists of a large ectodomain, a single pass transmembrane anchor, and a short C-terminal intracellular tail ( The globular N-terminal S1 subunit mediates the infection of receptor-expressing host cells;

it contains a receptor-binding domain (RBD) (Fig. 3B) , made by 193 amino acids fragment, which is responsible for recognizing and binding the cell surface receptor (e.g., ACE2, see below). On the other hand, the S2 domain mediates viral-membrane fusion through the exposure of a highly conserved fusion peptide, important for the entry of the viral genome inside the host. Multiple cleavage events activate the viral S protein with the involvement of several host proteases; the cleavage at the S1/S2 sites splits S into S1 and the S2 bioactive fragments, while another critical cleavage event, conserved in all coronaviruses, occurs at the so called S2' site (Jaimes et al 2020b) (see Fig. 3B ).

The cleavage at the S1/S2 sites, also termed priming, can be mediated by ACE2 and furin (and/or other bio-membrane anchored proprotein convertases, namely PoCo5B and PoCo7) (Hoffmann et al., 2020a) . Thus, in SARS-CoV-2 S the cleavage S1/S2 site 1 for furin (i.e., Pro Arg Arg Ala Arg689 ↓Ser Val) is conserved with respect to other CoVs ( Figure 3D ). On the other hand, like SARS-CoV, SARS-CoV-2 spike protein displays an additional putative cleavage recognition motif at the S1/S2 site 2 (Ile Ala Tyr ↓ Thr Met Ser) resulting from the four aminoacidic insertion (Ser Pro Arg Arg) (see Fig. 3C and D); this suggests that the SARS-CoV-2 might operate a peculiar mechanism to promote its entry into host cells (Coutard et al. 2020 , Zhang et al 2020a . Moreover, both SARS-CoV-2 and MERS-CoV display Pro685 at the S1/S2 junction. The turn created by Pro685 is important for the glycations of flanking residues; notably, the O-linked glycans Ser673, Thr678

and Ser686 are unique to SARS-Cov2 (Andersen et al 2020) . This feature might envisage an Oglycation somehow modulating the cleavability of the spike protein (Fig. 3C ).

The C-terminal of the S2 domain, known as the biomembrane-anchored stalk domain, anchors the S protein to the lipid transmembrane and it is involved in the viral entry (Belouzard et al., 2012) .

It contains the fusion peptide (FP), followed by an internal fusion peptide (IFP) and two heptan domains (HR)s preceding the transmembrane domain (TM) (see Fig. 3B ). Noteworthy, like SARS-CoV, the SARS-CoV-2 S2 domain contains a proteolytic site S2', found immediately upstream of the fusion peptide (Belouzard et al., 2009) , which displays the canonical furin-like cleavage site (i.e.,

Lys-Arg815↓Ser-Phe) and whose cleavage is critical for the fusion process (see Figs. 3C and 3D) (Coutard et al 2020) .

In addition to the canonical furin S2' cleavage site the SARS-CoV-2 S protein shows an additional potential furin-like cleavage site (referred as polybasic insert), absent in CoV of the same clade, which in turn broadens the spectrum of proteases that can be exploited by the virus (Hoffman 2020a, Coutard et al 2020, Andersen et al 2020)(see Fig. 3D ). As a matter of fact, trypsin-like proteases (TMPRSS2) and cathepsin L have also been shown to be involved in SARS-CoV-2

infection (Hoffmann et al., 2020b; Ou et al., 2020) . The formation of the S2 fragment and the further activation by the cleavage at the S2' site is an important determinant of the transmissibility and pathogenicity of many (but not all) coronaviruses (Millet and Whittaker, 2014; Jaimes et al 2020b) ,

inducing the fusion with the virion membrane and forming a pore for the passageway of viral material inside the cytoplasm.

Concerning the interaction with ACE2, the binding surface involves the RBD motif and it appears somewhat altered in SARS-CoV-2S with respect to other coronaviruses, displaying a much higher (about 6-20-fold) affinity than what reported for other viral Spike proteins (K D ~ 15 nM, as from Wrapp et al., 2020 ; K D ~ 5 nM, as from Lan et al., 2020) . Molecular modelling studies suggested that the higher affinity of SARS-CoV-2 RBD reflects the substitution of Leu472 (present in SARS-CoV)

with Phe486 (in SARS-CoV-2), allowing stronger van der Waals interactions with both Leu79 and Met82 of ACE2. Moreover, SARS-CoV-2S displays a Lys417 (which is Val404 in SARS-CoV), favouring a tighter association through a salt bridge formation with Asp30 of ACE2 (Lan et al., 2020; Yan et al., 2020 , Ulrich et al., 2020 .

Interestingly, low molecular weight heparin, which seems to induce a structural change of the S1 RBD, likely affects the interaction of RBD with ACE2 (Mycroft-West et al., 2020) , bringing about an affinity decrease of the S protein for ACE2 and partially impairing the viral invasion in lung and small intestine epithelial cells, where ACE2 is mostly expressed (Hamming et al., 2004) .

Furin (EC 3.4.21.75), also named PACE or PCSK3, is the prototype of subtilisin-/kexin-like proprotein convertase (PCSKs), encoded by a transcription unit in the upstream region of c-fes/fps proto-oncogene and it is ubiquitously expressed in eukaryotic cells and tissues (Garten, 2018) . Furin is a type I transmembrane highly specific endoprotease which cleaves the precursor forms of many secreted proteins during their transport along the constitutive secretory pathway. Notably, furin has been identified as an activating protease for fusion surface glycoproteins of a broad range of viruses (Garten, 2018) , displaying a broad optimum pH ranging between pH 5 and pH 8 (Thomas 2002) . Its Furin shuttles between the TGN and the cell membrane through the endosomal system, it is synthesized as a multi-segmented zymogen (100kDa) (Fig. 2) , and it is autocatalytically cleaved into the mature form (70 kDa) in the TGN. Furin ectodomain can be shed, and the soluble form also retains its catalytic activity in vivo and in vitro (Anderson, et al. 1993 ). This essential prodomain has a crucial role in the folding, activation and transport, and thus in the regulation, of furin activity through cell specific compartments.

Like other serine proteases, furin is characterized by a catalytic triad, made up of Ser368, His194, and Asp153 whereas Asn295 contributes to the oxyanion hole (Decha et al 2008) (Fig. 4B) .

Interestingly, the substrate-free enzyme is essentially inactive since the catalytic Ser368 residue is flipped over with respect to the active conformation. Substrate binding triggers the conformational change of Ser253, which brings about a flipping of Ser368 from the inactive to active conformation (Dahms et al., 2016) (Fig. 4B ).

The high specificity of furin proteolysis occurs at the C-terminal of a multibasic recognition motif, showing Arg-Xxx-Arg↓Xxx and Lys-Arg↓Xxx as preferred consensus sequences, often containing an additional Arg residue in the P4 position (Garten, 2018) . Unlike trypsin and chymotrypsin, the substrate-binding pocket is rigid and rich of negative charges, e.g. Glu 257 and Asp153 at the S1 and S2 substrate recognition sites, respectively. The rigidity of the substrate-binding pocket envisages a high selectivity for substrates, which indeed must properly fit inside the recognition site interacting with (at least) 6 residues forming the minimum binding surface (Dahms et al., 2018) . The substrate Arg residue is bound to the Glu 257 side chain of the S1 site, while the positively N-terminal charged residue (i.e., Lys) is bound to the Asp153 residue of the S2 site ( Fig.   4B ). In particular, Asn133 is a key component of the S5 substrate binding pocket together with Glu236 (Dahms et al., 2018) , while the S4 site involves two additional negatively charged residues (i.e., Asp236 and Asp 264) also present at the buried interface (Hardes et al., 2015; 2018) (Fig. 4B ).

Although the contribution of furin to SARS-CoV-2 S activation is not clear yet, its role has been demonstrated in many coronaviruses . Furin has been recognized important in mediating MERS-CoV S entry, with a prominent role in the two-steps activation of the spike protein (Hoffman et al 2018, Millet and Whittaker, 2014) .

Beside a canonical furin-like cleavage site, which is shared with other CoVs (i.e., HCoV-OC43, MERS-CoV, and MHV-A59) (Coutard, et al 2020) , the SARS-CoV-2 S protein displays at the S1/S2 site a 4 amino acids insertion which provides a minimal furin cleavage site (Pro-Arg-Arg-Ala-Arg689↓Ser-Val) and appears to create a larger S protein-furin interface, showing both positively charged residues (such as Arg185, Arg193, Lys261 and Arg298) (Fig. 3C ) and negatively charged ones of the catalytic site. It is supposed that furin attacks this cleavage site during virus egress (Millet and Whittaker, 2014) , facilitating the S protein priming and providing a gain-of-function to the SARS-CoV-2 for efficient spreading in the human population, as compared to other b lineage of βcoronaviruses. Therefore, the inhibition of such a process indeed might represent the basis for a successful antiviral strategy.

Because of the key role of furin in cancer and several infectious diseases, including Human

Immunodeficiency virus (HIV) and coronaviruses (Hallenberger et al., 1992; Thomas, 2002) , its suitability as a therapeutic target has raised significant interest for several years. Up to now various compound classes have been identified as promising lead compounds for drug development (Couture et al., 2015) (see Table 1 ).

A variety of approaches has been proposed to inhibit furin activity and some protein-based inhibitor variants have been engineered to develop powerful inactivators of furin. Among them, the α-1

antitrypsin Portland (α1-PDX), a variant of the naturally occurring serine protease inhibitor α-1 antitrypsin, is able to efficiently inhibit furin (almost irreversibly due to its strong affinity) and to prevent the processing of HIV-1 Env and measles virus F in vitro (Anderson et al., 1993; Watanabe et al., 1995; Dufour et al., 1998 ) (see Table 1 ). Similarly, peptides have been derived from the cleavage site of influenza A virus hemagglutinin, where polyarginines compete with natural furin substrates (Shiryaev et al., 2009; Cameron et al., 2000) .

Furthermore, the crystal structure of furin allowed the targeted modelling of non-peptidic inhibitors, such as streptamine-based compounds. Upon addition of guanidine residues, streptamine derivatives mimic the cationic furin cleavage site and inhibit its enzymatic activity in vitro in the nanomolar range (Jiao et al., 2006) . Notably, a 2,5-dideoxystreptamine-based small molecule inhibitor was found to interact with furin showing an unusual binding mode, different from a peptidebased substrate, which inhibits furin with K i = 46 nM. In particular, one molecule of inhibitor anchors at the S4 pocket of the enzyme, directly interfering with the conformation and function of the catalytic triad, while a second molecule shows weaker binding and interacts with a distant, less conserved region of furin (Dahms et al., 2017) 

Several effective synthetic furin inhibitors have been developed, most of which exhibit multi-basic peptidyl moieties mimicking the substrate sequence (Braun and Sauter 2019; Cameron et al., 2000) .

To increase their stability, and thus their efficiency, several approaches have been applied.

In this regard, the most powerful peptidomimetic furin inhibitors were based on the prototypical compound dec-Arg-Val-Lys-Arg-CMK (where dec refers to decanoyl group and CMK to chloromethyl ketone) ( Fig. 4C and Table 1 ), by coupling appropriate multi-basic substrate sequences to a P1 arginyl chloromethyl ketone group (Henrich et al., 2003) . The addition of the CMK moiety has proven useful as it irreversibly alkylates the His194 residue in the active site of furin, blocking its activity (Henrich et al., 2003 ) (see Fig. 4C and Table 1 ); dec-Arg-Val-Lys-Arg-CMK has also good cell permeability properties, which in turn enhance its efficacy (Garten et al., 1989) . Dec-

inhibiting furin-mediated processing of the hepatitis B e antigen (HBeAg) precursor into mature

HBeAg (Pang et al., 2013) . It was also reported that it is able to inhibit furin-mediated cleavage and fusion activity of viral glycoproteins, and acts as an antiviral agent against different viruses, including

HIV (Hallenberger et al., 1992) , Chikungunya virus (Ozden et al., 2008) , chronic HBV, influenza A, Ebola virus infection (Pang et al., 2013) and papilloma virus (Day and Schiller, 2009) . Recently, the efficacy of dec-Arg-Val-Lys-Arg-CMK as an anti-flavivirus agent (against Zika virus and Japanese encephalitis virus) has been demonstrated in both mammalian cells and mosquito cells with significant antiviral activities in terms of the reduction in virus progeny titre, in viral RNA and protein production (Imran et al., 2019) .

In the context of the coronavirus infection, dec-Arg-Val-Lys-Arg-CMK inhibited the processing of MERS-S protein, in a concentration-dependent manner, and had no effect on SARS-CoV-S expression, as expected from substrate specificity (Millet and Whittaker, 2014; Gierer et al., 2015) . Noteworthy, this furin inhibitor has been shown to block SARS-CoV-2 S processing at the S1/S2 site (Hoffmann et al., 2020c) , strengthening the idea that indeed furin is involved in the S1/S2

priming.

Nevertheless, as a result of the cytotoxicity of CMK-based inhibitors and of the instability of the CMK moiety, the potential therapeutic applications of these molecules remain limited to topical applications, such as the treatment of papillomavirus (HPV) skin infections (Henrich et al., 2003; Couture et al., 2015) . However, the incorporation of amino acid analogues, such as D-amino acids, decarboxylated P1 arginine mimetics, and 4-amidinobenzylamide (Amba), increased the stability of peptide-derived furin inhibitors. The most powerful compound, Phac-Arg-Val-Arg-Amba (Phac being a phenylacetyl group), inhibits recombinant furin with K i = 0.81 nM (Becker et al., 2010) .

Despite its excellent activity in vitro, Phac-Arg-Val-Arg-Amba showed reduced potency (IC50 ~ 10 μM), in a cellular assay, as an inhibitor of the cleavage of the fowl plague hemagglutinin of the H7 subtypes of the avian influenza viruses, possessing a multi-basic furin cleavage site; this limited efficacy might be related to a reduced ability of this inhibitor to target intracellular furin. The same authors also showed that this inhibitor was able to reduce feline panleukopenia virus propagation in a long-term infection test (25 μM of inhibitor over a period of 72 h, see Table 1 ).

Another powerful inhibitor of furin is a peptido-mimetic (i.e., 4-(guanidine methyl)-phenyl acetyl-Arg-Tle-Arg-4-Amba (MI-1148), where Tle refers to tert-leucine, also named 3methylvaline or tert-butylglycine, see Hardes et al., 2015) , which displays a 300-fold increase of the affinity (= 5.5 pM, see Hardes et al., 2015) for the substrate pocket, essentially blocking the furin activity (see Table 1 ). Inhibitor MI-1148 was shown to have a significant protective effect against anthrax and diphtheria toxin and to be active against H5N1 and H7N1 avian influenza viruses (HPAIV) and canine distemper viruses (CDV) propagation in cell culture. Interestingly, MI-1148, its P2 Lys analogue MI-1554 (4-guanidinomethyl-Phac-Arg-Tle-Lys-4-Amba, K i = 8.5pM, see Hardes et al., 2017) and several cyclic hexapeptide derivatives were recently tested as inhibitors of the proteolytic activation and replication of respiratory syncytial virus in cells (Van Lam van et al., 2019) (see Table 1 ). Significant antiviral activity was found for both MI-1148 and MI-1554 linear inhibitors, whereas a negligible efficacy was determined for the cyclic derivatives. The authors have speculated that the specific chemical structure of MI-1148 and other close linear analogues might enable enhanced cellular uptake, providing improved intracellular inhibitory potency.

A key discovery in understanding the mechanism of SARS-CoV-2 infection concerns the role of the androgen-responsive transmembrane serine protease 2 (TMPRSS2), a cell-surface protein that has been shown to facilitate the SARS-CoV-2 entry in the human airways by cleaving the viral Spike (S) protein (Lin et al., 1999; Jacquinet et al., 2001; Hoffmann et al., 2020a) .

TMPRSS2 (EC 3.4.21.109) is preferentially expressed in several epithelial tissues, such as prostate, kidney, colon, small intestine, pancreas, and lungs (Lin et al., 1999; Jacquinet et al., 2001; Lucas et al., 2008; Hoffmann et al., 2020a) . The physiological role of TMPRSS2 is unknown yet, even though it has been demonstrated that the expression of TMPRSS2 in lung cancer cell line A549

and prostate cancer cell is androgen-dependent (Lin et al., 1999; Mikkonen et al., 2010 , Shen et al., 2017 . TMPRSS2 is also expressed in the cardiac endothelium, kidney, and digestive tissues, which indeed are target tissues for SARS-CoV-2 infection. As a matter of fact, among the clinical complications of COVID -19 myocardial and acute kidney injuries are reported together with gastrointestinal symptoms (Madjid et al., 2020; Strope et al., 2020; Pan et al., 2020) . Furthermore, since TMPRSS2 is also expressed in microvascular endothelial cells of the blood vessels, the SARS -CoV-2 virus may bring about endothelial dysfunction with associated thrombosis (Bertram et al., 2012; Strope et al., 2020) .

Notably, epidemiological studies, carried out in several countries (i.e., China, Italy and the United States), suggest that the incidence and severity of the diagnosis of COVID-19 and other TMPRSS2-dependent viral infections are higher in men than in women. In this regard the role of TMPRSS2 in prostate cancer and the androgen-dependent TMPRSS2 expression has led to speculate that the prevalence of COVID-19 cases in men may possibly be related to TMPRSS2 (Stopsack et al., 2020) .

TMPRSS2 gene is located on human chromosome 21q22.3 and includes14 exons (Paoloni-Giacobino et al., 1997; Jacquinet et al., 2001) . A feature of the TMPRSS2 gene is that several androgen receptor elements (AREs) are located upstream of the transcription start site and the first intron of the TMPRSS2 gene (Lin et al., 1999; Mikkonen et al., 2010; Park, 2010; Shen et al., 2017) . TMPRSS2

gene encodes for a predicted protein of 492 amino acids that belongs to the type II transmembrane serine proteases (TTSPs) family (Bugge et al., 2009; Antalis et al., 2011) . The TTSP family is

protease domain of the chymotrypsin (S1) fold that contains the catalytic His, Asp, and Ser residues, and (iii) the "stem region" that contains a mixture of one to eleven protein domains of six different types (Fig. 5A ). TTSPs are synthesized as single-chain precursor and their activation produces a twochains form which is stabilized by a disulfide bridge, anchoring the active form to the cell membrane.

Nineteen human TTSPs have been identified and may be divided into four subfamilies, namely

Hepsin/TMPRSS, Matriptase, HAT/DESC, and Corin (Bugge et al., 2009; Antalis et al., 2011) .

To date, the three-dimensional structure of human TMPRSS2 protein has not been solved, since it displays a high percentage of coiled structure, a theoretical isoelectric point of 7.42, and a high surface hydrophobicity (Paoloni-Giacobino et al., 1997; Mushtaq et al., 2020) . Full length structural models

show that TMRPSS2 has a considerable structural homology with the serine protease hepsin (PDB ID: 1Z8G) (Herter et al., 2005) . In detail, the TMPRSS2 structural model ( The catalytic mechanism of the TMRPSS2 involves a catalytic triad of three amino acids, namely Ser441 (nucleophile), Asp345 (electrophile), and His296 (base). The catalytic reaction hydrolyzes the substrate by a two-steps mechanism, that is (a) the acylation step, which involves the formation of a covalently linked enzyme-peptide intermediate and the loss of a peptide fragment, followed by (b) the deacylation step, characterized by a nucleophilic attack on the intermediate by water, leading to the hydrolysis of the peptide (Fastrez and Fersht, 1973; Antalis et al., 2011) . To date, TMPRSS2 substrate specificity and catalytic properties have not been well characterized (Antalis et al., 2011) . 5B ).

Since the key residues of TMPRSS2 interact with amino acids flanking the cleavage site of S protein, it has been suggested that, upon interaction with TMPRSS2, the protein S may undergo a conformational change needed for the fine positioning of the cleavage site (i.e., residues Arg685/Ser686 and/or Arg815/Ser816) into the active site cleft (Mushtaq et al., 2020) .

Alpha-1-antitrypsin (A1AT) A1AT is a small protein, synthesized in the liver and present in plasma at high levels (0.9 g/L), its concentration displaying a six-fold increase under acute inflammation (Guttman et al., 2015) .

In the lungs, A1AT acts as a protective protein of the tissue damage and inflammatory response blocking the action of proteases involved in the cleavage of several structural proteins and processing several mediators of the innate immune response. It has been speculated that A1AT may reduce the pathogenicity of COVID-19 both by inhibiting the alveolar inflammatory response and by acting as a TMPRSS2 inhibitor, blocking the entry of the virus into the host cell (Azouz et al., 2020) .

AEBSF is a small molecule that blocks nonspecifically the protease activity (including TMPRSS2), occupying the S1 pocket of trypsin-like serine proteases and leading to a covalent sulfonylation of the active site (Seelwood et al., 2005; Azouz et al., 2020) . It brings about a decrease in the levels of both H1N1 and H7N7 nuclear proteins within the lung tissue of mice infected with influenza; further, AEBSF partially inhibits also the fusion of the mouse hepatitis coronavirus (Burkard et al., 2014) .

Bromhexine hydrochloride (BHH) is a drug used as a mucolytic and cough suppressant that shows specific inhibition of TMPRSS2 (IC 50 = 0.75 μM). Given that BHH is an FDA-approved drug with no significant adverse effects, it could be used for treatment of coronavirus infections as an inhibitor of TMPRSS2 (Lucas et al., 2014; Shen et al., 2017; Sonawane et al., 2020) .

Camostat mesylate is considered the standard inhibitor of TMPRSS2 and it has been demonstrated that it is able to inhibit the proteolytic activity of TMPRSS2 even at the lowest concentration of 100 nM, thus reducing the probability of SARS-CoV-2 penetration in cell experiments in vitro (Kawase et al., 2012; Hoffmann et al., 2020a; Azouz et al., 2020 ) (see Fig. 5C ).

Similarly, the Nafamostat, a structural analog of Camostat, blocks SARS-CoV-2 infection of human lung cells with 15-fold higher efficiency than Camostat mesylate; this makes it a good compound to enter clinical trials for COVID-19 treatment (Hoffmann et al., 2020b) .

A structural model of TMPRSS2-Camostat complex suggests that the predicted active site of the TMPRSS2 consists of the amino acid residues Asn146, Arg147, Cys148, Val149, Arg150, Leu151, Asp187, Met188, Tyr190, Ile221, Tyr222, Lys223, Asn368, Pro369, Gly370, Met371, Lys449, Asn450, Ile452, and Trp454 (Mushtaq et al., 2020; Sonawane et al., 2020) . Camostat interacts with the TMPRSS2 Val28, Asp440, Thr459, Ser460, Trp461, Tyr474 by van der Waals interactions and establishes seven hydrogen bonds with four key residues of the protease active site (i.e., Asn146, Cys148, Asp187, and Asn450) (Mushtaq et al., 2020) . In detail, Asn146 forms an arene cation and backbone acceptor H-bonds, while Cys148 forms an arene-H bond with the benzene ring of the ligand. Asn450 forms two hydrogen bonds with the anhydrous carbonyl oxygen, with side chain acceptor and backbone acceptor. Asp187 forms an acidic hydrogen bond with the primary amine and a sidechain donor hydrogen bond with the secondary amine of the ligand (Mushtaq et al., 2020) . In addition, different groups of Camostat mesylate form strong hydrogen bonds with two amino acid residues of the TMPRSS2 catalytic triad (i.e., His296 and Ser441) ( Figure 5C ). amino acid residues (i.e., Asn146, Arg147, Arg150, Lys449, and Asn450) are side chain acceptor, and two residues (i.e., Asn146 and Arg147) are concurrently backbone acceptor and donor. It is known that the geniposide is an inhibitor of 5-lipoxygenase (Nishizawa et al., 1988) and it has antiangiogenic activity (Zhang et al., 2020c) as well as anti-asthmatic properties (Huang et al., 2017) .

As it happened in the past for the HIV, HCV, influenza viruses, SARS-CoV and other etiological agents, today a great effort is being devoted to the SARS-CoV-2 pandemia, showing its own peculiar protein targets. In the absence of an effective vaccine, inhibitor repurposing or de novo drug design may offer an effective strategy to combat the alarming SARS-CoV-2 pandemia.

As reported above, an interesting potential antiviral strategy concerns the inhibition of ACE2dependent viral entry, interfering with the cleavage of SARS-CoV-2 spike protein to arrest the viral propagation.

Within the lineage b of β-coronaviruses, SARS-CoV-2 has revealed a dominant importance of furin, which was not observed before, suggesting that furin inhibitors may participate to halt virus propagation. However, despite considerable evidence of in vitro and in vivo efficacy of furin inhibitors, there is very limited clinical trial evidence to support or reject the use of these compounds in a therapeutic context. Moreover, one of the greatest limitations for the development of furin inhibitors as therapeutic agents has been related to potential health consequences. In this regard, since furin-like enzymes are involved in a multitude of cellular processes (Roebroek et al., 1998) , an important issue would be to avoid systemic inhibition that may lead to relevant side effects. While many of the inhibitors, described above, strongly reduce furin activity, most of them also inhibit other PCSKs, recognising the same or similar polybasic cleavage sites (Couture et al., 2015) . Although a selective inhibition of individual PCSKs can be achieved, systemic long-term inhibition will most likely have detrimental effects. Therefore, one crucial point in the therapeutic application of furin inhibitors is to limit the systemic inhibition that may lead to some adverse effects.

It must be stressed that, differently from viral targets, furin (like any protein hijacked by the virus system) is an attractive target as it is not expected to develop drug resistance. On the other hand, as for Ebola virus, although a furin cleavage site has been clearly demonstrated, blocking the furinmediated cleavage of glycoprotein does not result in a reduction of viral replication under cell culture conditions, suggesting that the inhibition of furin activity may not always produce beneficial effects (Neumann et al., 2002) . Therefore, to encourage further developments of furin inhibitors additional proofs-of-concept are required at each step of the different infectious processes.

An additional important aspect concerns the assessment of cell penetration properties for the developing inhibitors. Since furin localizes both in intracellular compartments (i.e., secretory pathway, endosomal pathway) and at the cell surface, inhibitors will have to reach both destinations to ensure full cleavage inhibition. Of note, several furin inhibitors (e.g., polyarginine and dec-Arg-Val-Lys-Arg-CMK) exhibit good cell permeability properties, which in turn enhance their efficacy (Fuchs and Raines, 2004; Garten et al., 1989) .

A possible strategy to limit viral infections is the restriction of the trafficking of furin to trans-Golgi network or to early Golgi compartments, where the pro-protein convertase remains inactive (Coutard et al., 2020) . In this regard, streptamine derivatives may be particularly promising for targeted therapy, since the positioning of the guanidyl substituents leads to a localisation of the inhibitor into distinct subcellular compartments, such as endosomes or the Golgi complex (Klein-Szanto and .

Overall, despite the crucial role of furin, it is possible that acute inhibition over a limited time interval may lead to vastly beneficial effects in tackling viral infections, especially in the case of a substantial ineffectiveness of vaccines or other drugs. Future studies will have to better define shortand mid-term term toxicity profiles and thus to establish the pharmacological safety of this type of intervention. Thus, although the therapeutic application of furin inhibitors may show several pitfalls, it is certainly a potential treatment option against SARS-CoV-2 that should be further pursued .

Although Camostat mesylate blocks COVID-19 entry into the cell by inhibiting the cellular host TMPRSS2 (see above sections), more testing is required before it can possibly be labelled as an effective therapy for the treatment of COVID-19.

Considering the central role of TMPRSS2 in activating SARS-CoV-2 and other respiratory viral infections, to interfere on its expression or on its activity indeed could represent a promising approach to treat respiratory COVID-19. Therefore, the knowledge of the amino acids that make up the active site of TMPRSS2 and the cleavage site of SARS-CoV-2 favors the targeted design of efficient drugs against COVID-19. The structural information, obtained by computational analysis, combined with experimental in vitro and in vivo validation, represents the basis for designing and discovering new protease inhibitors to be used for preventing the entry of SARS-CoV 2 into human host cells.

Among potential anti-COVID-19 drugs we report the phytochemical geniposide; this TMPRSS2 inhibitor should be validated for treatment of coronavirus infection as it does not show toxicity in humans, since it has been reported that geniposide cannot cross the blood-brain barrier and it is not absorbed by the gastrointestinal tract . In addition, geniposide protects against sepsis-induced myocardial dysfunction by activating AMPK which suppresses myocardial reactive oxygen species (ROS) accumulation (Shan et al., 2017) .

Two protease inhibitors (i.e., camostat, at a concentration of 0.1-10 µg/ml, and nafamostat, at a concentration of 0.01-1 µg/ml) inhibit the coronavirus replication in human airway epithelial cells, displaying an additive effect in combination with interferon (Yamaya et al., 2020) .

The antiviral action of nitric oxide (NO) has been reported for the treatment of several DNA and RNA virus families (Colasanti et al., 1999) . Therefore, a novel approach to arrest SARS-CoV-2 life cycle could be targeting cysteines of TMPRSS2 through a covalent attachment of a nitrogenous group (-NO). As NO and NO donors are able to nitrosylate thiol group, inhaled NO in COVID-19 patients could potentially be an effective therapy (Ignarro, 2020) .

The polyproteins encoded by ORF1a and ORF1b are auto-catalytically cleaved into 16 different nonstructural proteins (nsp) by the two viral proteases (i.e., Mpro and PLpro) . The N-terminal part, which is cleaved by PLpro, contains three proteins, namely nsp1 and nsp2, which help modulating the host response, and nsp3. PLpro activity also plays a key role in other functions, such as the deubiquitination of host polyubiquitin chains and the formation of the viral double-vesicles membranes (see Fig. 1 ). The rest of pp1a and pp1ab are self-cleaved by Mpro, giving rise to 13 proteins which, except for Mpro itself, play different roles in RNA replication (i.e., helicase, proofreading exoribonuclease, endoribonuclease and methyltransferase activities). It is worth citing here that the polyprotein pp1ab, which is encoded when ribosomal frameshift occurs, also contains the RNA-dependent RNA replicase, a common target for anti-viral inhibitors.

Besides SARS-CoV-2, only six other human coronaviruses have been identified so far and belong to two distinct genera, namely (a) Alphacoronavirus (i.e., (i) HCoV-NL63 and (ii) HCoV-229E) and (b) Betacoronavirus (i.e., (i) HCoV-OC43, (ii) HCoV-HKU1, (iii) the severe acute respiratory syndrome SARS-CoV, and (iv) the Middle East respiratory syndrome MERS-CoV) (Tang et al., 2015) .

The multiple-sequence alignment of the main proteases from the seven human coronaviruses ( Figure 6A ) shows that the active site (i.e., residues Thr24-Leu27, His41-Tyr54, Phe140-Cys145, His163-Pro168) is highly conserved in all the coronavirus Mpros, clearly indicating its specificity.

Interestingly, from a pairwise alignment, SARS-CoV-2 Mpro shows more similarities to its SARS-Cov homologue (96% identity and 99% similarity) than with any of the other six Mpros from human coronaviruses (average identity 50%, average similarity 64%). Indeed, only very few residues in SARS-CoV-2 are substituted with respect to the SARS-CoV counterpart, that is Thr35Val, Ala46Ser, Ser94Ala, Lys180Asn, Ala267Ser, and Thr285Ala. All these mutations are located in poorly conserved regions on the surface of Mpro with the exception of Ser46, which is located in the proximity of the active site entrance; the Ala267Ser mutation is also observed in the HCov-NL63

strain. Although such a small structural change would be not expected to substantially affect the binding of small molecules to the binding sites, structural and molecular modelling studies show that 

In the mature active form, Mpro (EC 3.4.22.69) is found as a homodimer. Each protomer is formed by three structural pseudo-domains, namely two antiparallel-β-barrel domains (domains I and II, residues Phe8-Tyr101 and Lys102-Pro184, respectively), and a five-fold antiparallel-α-helix domain (domain III, residues Thr201-Thr303) (Yang et al., 2003) ( Figure 6B ). The Mpro enzyme resembles the structure of cysteine proteases, although in the active site the third catalytic residue is missing; thus, the active site is formed by the catalytic dyad His41-Cys145, which forms the "oxyanion hole"

together with the main-chain amides of Gly143 and Ser144 (Zhang et al., 2020d ) (see Fig. 6B ). The

His-Cys dyad is highly conserved among the coronavirus proteases and shows significant structural homologies with the 3chymotrypsin protease (3Cpro) of rhinoviruses, which, however, contain a catalytic triad composed of His, Cys, and Glu or Asp (Yang et al., 2003 , Lee et al., 2009 . In this context, it is also worth noting that, while the autocatalytic process of viral polyproteins is performed The Mpro active site has different subsite pockets which confer a high substrate specificity for each residue in the recognized cleavage sequence (Ziebuhr et al., 2000; Anand et al, 2002) . These specificity pockets are named as S1, S2, S4, S1' after the residues in position P1, P2, P4, P1' of the substrate sequence. When bound to coronavirus Mpro, the P4 and P3 residues adopt a β conformation, inducing structural adaptation of the corresponding subsites, while both P1 and P2 side-chains are allocated in the pre-formed S1 and S2 specificity pockets (Anand et al., 2002) ( Figure 6C ).

For SARS-CoV and MERS Mpro a direct role in the S1 shaping was found to be played by the protonation of two histidines (i.e., His163 and His172 in SARS-CoV sequence) flanking the S1 pocket (Tan et al., 2005) . Interestingly, a particularly stable water molecule seems also to play an important role by forming a water-bridge that stabilizes His163 and His172 conformations (Zheng et al., 2006) . Additionally, available crystallographic structures of Mpro from SARS-CoV, SARS-CoV-2 and MERS-CoV reveal that the P1 glutamine side chain may interact with the imidazole side chain of His163 which is located at the very bottom of a hydrophobic pocket (i.e., residues Phe140, Ile141, Leu165, Glu166 and His172) which flanks the S1 subsite ( Fig. 6C ) (Hegyi et al., 2002; Zhang et al., 2020d) . Among the other subsites of coronavirus Mpro, the S2 specificity pocket, formed by residues Leu164, Pro188, Ile51, His41 and Thr47, is large enough to display a high specificity for Leu side chain (Fig. 6C ). Molecular modelling also suggested that the flexibility of regions 140-146 and 184-197, which encompass S1 and S2 binding pockets, is crucial to accommodate substrate and analogs (Zheng et al., 2007; Komatsu et al., 2020) .

The quaternary structure of Mpro may also contribute to the modulation of enzyme activity; thus, the dimer interface area, which is constituted by the two domains III, seems to play a pivotal role by allowing the ion-pair interaction between residue Glu290 of one protomer and Arg4 of the other one. Moreover, in the mature protein, the "N-finger" (the N-terminal residues) of each monomer forms stable hydrogen bonds with Phe140 and Glu166 of the other protomer, squeezing the outerwall of S1 and shaping the S1 pocket to become catalytically competent (Anand et al., 2002; Zhang et al., 2020d , Zheng et al., 2007 . An additional contribution to the dimer stabilization may originate from the direct interaction between the residues 285 of each protomer (Thr and Ala in SARS-CoV and SARS-CoV-2 MPro, respectively); in SARS-CoV MPro this interaction occurs through a H-bond between the two Thr285 hydroxyl groups. However, this interaction, though tightening the dimer assembly in SARS-CoV Mpro, does not seem to affect the catalytic activity, since it is closely similar for the two Mpros (Anand et al., 2002) .

additional amino acid substitutions (usually located far from the catalytic site, see Fig. 6A ), but two of them (namely Lys180Asn and Ala46Ser) are potentially relevant, since they are found in the deep hydrophobic pocket below the active site and in the loop region flanking its entrance (i.e., Cys44-Pro52 loop). Although Lys180Asn is located too far to directly contribute to substrate binding, it clearly extends the hydrophobic inner region of the site. On the other hand, even though the Ala46Ser substitution is not expected to have significant effect on the binding of small ligand compounds , molecular dynamics simulations showed that it increases the flexibility of the Cys44-Pro52 loop modifying the active site entrance and likely playing a role in substrate recruitment (Bzówka et al., 2020) . Further, a comparison of differing residues between SARS-CoV and SARS-CoV-2 Mpros, has shown that the Cys44-Pro52 loop and the Phe185-Thr201 linker loop are evolutionarily correlated, so that mutations, occurring in these flexible loops, can render them more stable. Interestingly, molecular dynamics simulations of SARS-CoV and SARS-CoV-2 Mpros also showed that, despite the high sequence/structure similarity, their active site binding cavities have significantly different shape with an overall accessible volume 50% larger in SARS-CoV Mpro than in its SARS-CoV-2 counterpart (Bzówka et al., 2020) . Thus, these finding suggests that repurposing SARS-CoV drugs for SARS-CoV-2 may not work well (Bzówka et al., 2020) .

Overall, several studies proved that the few differences between SARS-CoV-2 Mpro and homologue proteases from other human coronaviruses may have significant effects in both dimer stabilization (residue 285) and in active site plasticity (residues 46 and 180).

As already reporded above, the Mpro is not the only protease that processes the post translational maturation of the viral polypeptide product but there is also a papain-like protease (PLpro) (Fig. 2) .

Unlike Mpro, SARS-CoV and SARS-CoV-2 PLpro share only 83% sequence identity with substantial variations occurring on the protein surface. These differences are expected to influence the binding of ligands to the PLpro but not the overall secondary and tertiary structures, suggesting that inhibitors developed for SARS-CoV would possibly work as lead compounds also for the development of SARS-Cov-2 PLpro drugs (Morse et al., 2020) .

The papain-like protease (PLpro) is part of the multi-domain/multi-functional non-structural protein 3 (nsp3) which is highly conserved among coronaviruses. Besides the proper proteinase domain, nsp3 also contains two ubiquitin-like (Ubl) domains, an ADP-ribose-1″-phosphatase domain, a nucleic acid-binding domain and trans-membrane domains (Rut et al., 2020) . The catalytic domain of PLpro recognizes the tetrapeptide Lys-Xxx-Gly-Gly motif at P4-P1 positions found in-between viral non-structural proteins (i.e., ns1 and 2, ns2 and 3, ns3 and ns4), but it shows a broad substrate specificity at P3 position. SARS-CoV-2 PLpro and SARS-CoV PLpro differ by 54 residues, but the P3 and P4 sites are almost identical.

An efficient inhibition of a multimeric protease can be gained not only by targeting the active site but also by interfering with the stability of its structure and with the modulation of its activity. As an example of this, we can mention darunavir which blocks dimerization of the HIV-1 protease (Hayashi et al 2014) , thus impairing its activity and HIV replication. As previously mentioned, proteases may appear as evolutionary distant as differing for their active-site, but still share some important functional properties. As a matter of fact, in the following sections we will report not only molecules specifically tailored for the active site of Mpro and/or PLpro, but also on molecules, which, though designed for other types of proteases (such as HIV-1), may nonetheless interfere with non-specific processes required for the activity of SARS-CoV-2 proteases.

In the following, we will present a discussion on inhibitors for human coronavirus Mpro. First, results for known Mpro inhibitors will be presented and recent findings on natural compounds or repurposed drugs as SARS-CoV-2 Mpro inhibitors will be also thoroughly discussed. It is worth noting that the urgency for an effective treatment against COVID-19 has deeply stimulated the scientific community Over one decade ago, in an interesting anti-SARS drug screening research, 59,363 compounds were docked, 93 were selected for inhibition assays, and finally 21 showed inhibition against SARS-CoV Mpro with IC 50 ≤ 30 µM. Similar substructures were found in three databases identifying another 25 compounds that exhibited inhibition with IC 50 from 3 µM to 1 mM against SARS-CoV Mpro. The promising compounds were also thouroughly investigated by 3D-QSAR and pharmacophore approaches (Tsai et al., 2006) .

In the framework of the actual coronavirus pandemia, selected drugs, like favipiravir, amodiaquine, 2'-fluoro-2'-deoxycytidine, and ribavirin are not classified as protease inhibitors, but they were docked and evaluated as possible inhibitors of SARS-CoV-2 MPro. The amodiaquine showed the best binding energy ( Figure 7A ) (-7.77 kcal/mol), envisaging a high binding affinity, which was attributed to the presence of three hydrogen bonds, hydrophobic interactions between the drug and critical residues of the Mpro as well as to its electrophilicity index, basicity, and dipole moment (Hagar et al., 2020) .

The peptidomimetic α-ketoamides represent a class of prototypical inhibitors of Mpro.

Molecular docking and molecular dynamics simulations were used to characterize the interaction of an α-ketoamide analogue with the active site of the SARS-CoV-2 Mpro. The predicted Glide score and molecular dynamics indicated clearly that α-ketoamide analogues bind the Mpro more tightly than the amoxicillin used as control (Liang et al., 2020) . One of them, synthesized and defined as 11r, turned out to be particularly effective on MERS-CoV Mpro (K D ~ 400 pM) and moderately effective on SARS-CoV Mpro (K D ~ 2 µM) (Zhang et al., 2020e) , resulting somewhat less powerful on SARS-CoV-2 Mpro (K D ~ 3 µM) (Zhang et al., 2020d) . The inhibitory power was then significantly increased (K D ~ 0.7 µM, see Zhang et al., 2020d) by substituting the P2 cyclohexyl moiety with a smaller cyclopropyl ring, suggesting that the S2 binding pocket is less flexible than originally thought. This was partially confirmed by a computational study, which, though observing a relevant flexibility of several domains of Mpro, detected a particular rigidity of its active site (Islam et al., 2020 ).

An interesting investigation identified a series of novel peptidomimetic aldehydes. These new compounds were designed so as to maintain the aldehyde as warhead in P1' and holding the S1'pocket of the Mpro active site. The most promising inhibitors, defined as 11a and 11b, exhibited anti-SARS-CoV-2 Mpro activity (IC 50 = 0.053 μM and IC 50 = 0.040 μM, respectively), being also effective on the anti-SARS-CoV-2 infection activity in cell culture (EC 50 = 0.53 μM and EC 50 = 0.72 μM, respectively). Both compounds showed also good results for a preliminary pharmacokinetic evaluation .

Phytochemicals (i.e., molecules derived from plants and often adopted for food or traditional medicine purposes) are emerging in the very recent literature as an alternative source of investigation for the inhibition of SARS-CoV-2 Mpro. Hereafter, a series of in silico screening on these compounds is reported (Fischer et al., 2020; Gupta et al., 2020; Gurung et al., 2020; Kumar et al., 2020a; Kumar et al., 2020b; Bhardwaj et al., 2020; Umesh et al., 2020; Enmozhi et al., 2020; Serseg et al., 2020; .

A first interesting approach was carried out by screening an impressive number (more than 606 million) of compounds. Shape screening, molecular descriptors relevant for pharmacokinetics and complex stability (estimated by molecular dynamics simulations) were used to significantly reduce the number of molecules to be studied. A final list of 9 compounds was selected and the natural compounds (-)-taxifolin from plant of Pinaceae family and rhamnetin from plant of Myrtaceae family were identified as best binders and thus potential inhibitors of SARS-CoV-2 MPro (Fischer et al., 2020) .

Alternatively, a great number of compounds (more than 250), derived from Curcuma longa L. were tested and two of them, namely (a) the C1 (1E,6E)-1,2,6,7-tetrahydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione) and (b) C2 (4Z,6E)-1,5-dihydroxy-1,7-bis(4hydroxyphenyl)hepta-4,6-dien-3-one) revealed a better binding score (-9.08 and -8.07 kcal/mol, respectively) with respect to the control shikonin and lopinavir (around -5.4 kcal/mol) (Gupta et al., 2020) .

Bonducellpin D from Caesalpinia bonduc ( Figure 7B ) showed high binding affinity (-9.28 kcal/mol) because its interaction is stabilized by four hydrogen bonds with Glu166 and Thr190 together with hydrophobic interactions established with eight residues. Moreover, Bonducellpin D exhibited a broad-spectrum inhibitory potential against SARS-CoV Mpro and MERS-CoV Mpro (Gurung et al., 2020) .

Three natural metabolites (like ursolic acid, carvacrol and oleanolic acid) passed ADME (i.e., Absorption, Distribution, Metabolism, and Excretion) property as well as Lipinski's rule of five and were candidates as potential inhibitors of MPro (Kumar A. et al., 2020a) .

Withanone, an active constituent from Withania somnifera, and the natural phenolic caffeic acid phenethyl ester component of propolis interact with the highly conserved residues of the substrate-binding pocket of SARS-CoV-2 Mpro, and their binding free energy were estimated comparable with that of the N3 protease inhibitor (Kumar V. et al., 2020b) .

Three bioactive molecules from Camellia sinensis (i.e., oolonghomobisflavan-A, theasinensin-D, and theaflavin-3-O-gallate) were selected after docking and molecular dynamics simulation approach on SARS-CoV-2 Mpro, and they were compared with antiviral drugs. The oolong tea (blue tea)-derived molecule oolonghomobisflavan-A showed the best score and a higher number of hydrogen bonds network with respect to all tested compounds (Bhardwaj et al., 2020) .

Metabolites and molecules from Indian spices, present in PubChem and Zinc databases, were also analyzed by bioinformatics approach, virtual screening tools and molecular dynamics. The best three molecules were a) carnosol from Rosmarinus officinalis, that exhibited hydrogen bonds interactions with residues present on the active site of SARS-CoV-2 MPro and also the highest binding affinity (-8.2 kcal/mol), b) rosmanol from Rosmarinus officinalis, (-7.99 Kcal/mol), and c) the triterpene glucoside arjunglucoside-I from Terminalia arjuna (-7.88 kcal/mol) (Umesh et al., 2020 ).

An endemic plant Andrographis paniculate, adopted in traditional medicine, provides a potential inhibitor of Mpro, that is the andrographolide, which displays good solubility, target accuracy and obeys the Lipinski's rule of five (Enmozhi et al., 2020) .

Further, three other natural compounds could be of interest, namely (i) hispidin from Pteris ensiformis, (ii) lepidine E, an alkaloid from the seeds of Lepidium sativum, and (iii) folic acid, which all bind tightly the enzyme forming hydrogen bonds with the residues of active site (Serseg et al., 2020 ).

An additional source of potential SARS-CoV-2 Mpro inhibitors seems represented by natural marine products. For example, among five tested marine natural products, the cytotoxic molecule fostularin 3 exhibited hydrogen and hydrophobic interactions with residues in the active site of Mpro . Additional promising inhibitors were phlorotannins from Sargassum spinuligerum, pseudotheonamides from sponge Theonella swinhoei, and also flavonoids. In particular, heptafuhalol A ( Figure 7C ) showed the lowest docking energy (−14.60 kcal/mol), associated to a network of hydrogen bonds with the acceptor residues of Thr24, Ser46, Asn142, Glu166, Pro168 and hydrophobic interactions with Met49, Met65, Leu141, and Pro168. After the molecular dynamic simulation and re-docking protocol the His41 residue, belonging to the catalytic dyad, is shown to establish a hydrogen bond with the hydroxyl residue of the ligand (Gentile et al., 2020) .

An effective alternative to non-specific Mpro natural inhibitors is provided by repurposed compounds, originally developed for other diseases or for protein inhibition in other human pathogens.

In an interesting study two libraries of drugs were docked against Mpro using three of the most common docking programs. Only the molecules with high consensus among the different algorithms were considered new promising SARS-CoV-2 Mpro inhibitors. The predicted candidates were:

perampanel, carprofen, celecoxib, alprazolam, trovafloxacin, sarafloxacin and ethyl biscoumacetate (Gimeno et al., 2020) .

Alternatively, a virtual screening of FDA-approved drugs was performed against the SARS-CoV-2 Mpro, giving the glecaprevir and maraviroc as the best inhibitors (Shamsi et al., 2020) .

Further, also selected anti-HIV drugs (e.g., saquinavir, ritonavir, lopinavir, and others) and anti-HCV drugs (e.g., simeprevir, faldaprevir, and asunaprevir) were docked against SARS-CoV-2 Mpro.

Indeed, simeprevir ( Figure 7D ), an approved HCV NS3/4A protease inhibitor, seems to be a promising lead compound, fitting quite well (-10.0 kcal/mol) in two hydrophobic pockets flanking the catalytic dyad dyad His41-Cys145 and inducing an opening of the substrate binding pocket, which weakens significantly the compactness of the active site (Calligari et al., 2020) .

Moreover, in addition to the aforementioned anti-HIV and anti-HCV drugs, a different study showed that best results were obtained with other compounds, like delavirdine, cefuroxime axetil, oseltamivir, and prevacid (Al-Khafaji et al., 2020) . Furthermore, a study found that the anti-protozoal emetine and hespedin seem to bind nearby the catalytic residues His41 and Cys145. The molecules were surrounded by other residues identified as Met49, Gly143, His163, His164, Glu166, Pro168, and Gln189 (Das et al., 2020) .

Not only anti-HCV and anti-HIV drugs but also the anti-influenza triazavirin was docked against SARS-CoV-2 Mpro and tested clinically in China for COVID-19 treatment (Shahab and Sheiki, 2020) . Viomycin, a nonribosomal peptide with antibiotic properties and administered for the treatment of Mycobacterium tuberculosis infection, was docked for Mpro embedding deeply inside the binding pocket and showing a higher number of hydrogen bonds with SARS-CoV-2 Mpro than N3 inhibitor (Mahanta et al., 2020) . A completely different category of drugs, like statins, have been docked with MPro; in particular pitavastatin, rosuvastatin, lovastatin, and fluvastatin may be novel molecules with inhibitory properties. In fact, pitavastatin ( Figure 7E ) has a binding energy greater than that of protease inhibitors nelfinavir and lopinavir, reported in the same study (Reiner et al., 2020) . Potential inhibitors of SARS-CoV-2 Mpro were also identified by a structure-guided virtual screening approach using inhibitor N3 as a starting reference. Interestingly, among the selected molecules, leupeptin, pepstatin A, birinapant, lypressin, and octreotide turned out to be remarkable potential inhibitors. All these molecules have applications spanning from anticancer therapy to widespread inhibition of different types of proteases (Mittal et al., 2020) . A structure-based virtual screening on SARS-CoV-2 Mpro was also performed using the ChEMBL database and thousands of other compounds as reference. The first result discussed was a hit of 64 drugs classified into antibacterial, antidiabetic, anti-inflammatory, cardiovascular, gastrointestinal, anti-HIV, and neuropsychiatric drugs. Among them, two potential anti-SARS-CoV-2 drugs were obtained from autodock vina docking simulations, namely a) curcumin (-7.3 kcal/mol), b) sepimostat (-7.9 kcal/mol), even though the best score was found for the eszopiclone (-10.0 kcal/mol) ( Figure 7F ) a drug used for the treatment of insomnia (Tsuji, 2020) .

Further, the antibiotic talampicillin and the anti-psychotic lurasidone have been identified by virtual screening as potential drugs worth being tested against SARS- CoV-2 MPro (Elmezayen et al., 2020 ).

An interesting molecular docking study compared the binding energy score of most promising molecules against SARS-CoV-2 MPro. It showed that O6K molecule had a binding score similar to N3 (−7.4 kcal/mol and −7.1 kcal/mol, respectively). Remdesivir and its metabolite (GS-441524) turned out to be slightly less effective (−7.0 and −6.4 kcal/mol, respectively), while the entecavir, which has a structure similar to that of GS-441524, displayed also a closely similar score of −6.4

kcal/mol (Huynh et al., 2020) . Notably, remdesivir, GS-441524 and entecavir might be multi-target potential inhibitors for both RNA-dependent RNA-polymerase (RdRp) and Mpro. In the same work, umifenovir, together with montelukast, a drug for the treatment of allergies and the prevention of asthma attacks, showed moderate binding score to Mpro ( −6.5 kcal/mol and −6.5 kcal/mol, respectively) while a lower score was found for chloroquine and hydroxychloroquine with −5.0 kcal/mol and −5.9 kcal/mol, respectively (Huynh et al., 2020) .

An important set of promising molecules with inhibitory effect on Mpro were also tested against the purified enzyme, different cell lines, as well as by co-crystallization with Mpro.

Baicalin and baicalein, two compounds from Scutellaria baicalensis, were considered as novel non-peptidomimetic inhibitors of Mpro, displaying also an antiviral activity in SARS-CoV-2 infected cells. Baicalin showed an IC 50 of 6.41 µM against the Mpro, while baicalein shows an IC 50 of 0.94 µM; K d of baicalin and baicalein binding to Mpro were 11.50 and 4.03 µM, respectively . The crystal structure revealed that baicalein binds Mpro in a core region of the substratebinding site between domains I and II also interacting with the the His41-Cys145 dyad, S1/S2 subsites and the oxyanion loop. Furthermore, Vero E6 cells were infected with SARS-CoV-2 in the presence of different concentrations of baicalin or baicalein. Baicalin and baicalein showed a dosedependent inhibition on the replication of SARS-CoV-2 with an EC 50 of 27.87 and 2.94 µM, respectively . Therefore, the cell-based antiviral activity of baicalin or baicalein is close to that of chloroquine (EC 50 = 2.71 µM) and hydroxychloquine (EC 50 = 4.51 µM) (Liu et al., 2020b ) (see Table 2 ).

A second study displayed a variety of different drugs all tested against purified SARS-CoV-2

Mpro. The groups considered were proteasome inhibitors, HIV protease inhibitors, γ-secretase inhibitors, HCV NS3-4A protease inhibitors, DPP-4 inhibitors, miscellaneous serine protease inhibitors, cathepsin and calpain protease inhibitors, miscellaneous cysteine protease inhibitors, matrix metalloprotease inhibitors, and miscellaneous protease inhibitors .

Boceprevir, an anti-HCV drug, inhibited the enzymatic activity of Mpro with IC 50 of 4.13 μM, and an EC 50 of 1.31 μM against the SARS-CoV-2 virus in the primary viral cytopathic effect (CPE) assay.

An interesting result was obtained with the protease inhibitor Gly-Cys-376 (a broad-spectrum inhibitor targeting Mpro in the picornavirus-like cluster), that showed promising antiviral activity with an EC 50 = 3.37 μM as well as an enzymatic inhibition with a value of IC 50 = 0.03 μM . Interestingly, in another recent work, Gly-Cys-376 showed a promising high affinity (IC 50 =26.4 nM and EC 50 of 0.91 μM) to SARS-Cov2 Mpro (Hung, 2020) . While ebselen and N3 displayed inhibition against SARS-CoV-2 with EC 50 values of 4.67 μM and 16.77 μM, respectively .

values of 2.07 and 0.49 μM, respectively, as well as the purified Mpro showing IC 50 = 0.97 μM and IC 50 = 0.45 μM, respectively. The common feature that confers inhibitory capacity of these promising drugs is the structural core of α-ketoamide (i.e., the warhead). The identified compounds were more powerful and selective than the reported SARS-CoV-2 Mpro inhibitors ebselen, N3, and 13b . Previously characterized molecules, such as organo-selenium compound ebselen, disulfiram, tideglusib, and carmofur exhibited EC 50 values of 0.67 μM, 9.35 μM, 1.55 μM, and 1.82

μM respectively .

inhibitory effect (IC 50 of 0.55 μM) better than other drugs tested, such as the disulfiram (4.67 μM),

which was taken as positive control for the bioassay . Furthermore, dipyridamole and montelukast sodium showed a global inhibitory function on NF-kB signalling and inflammatory responses during viral infection .

Cinanserin was considered an inhibitor of SARS-CoV (IC 50 = 4.92 μM) , but the inhibition of the purified SARS-CoV-2 Mpro was not high (IC 50 = 125 μM), so as only moderate inhibition was observed against SARS-CoV-2 with an EC 50 of 20.61 μM from qRT-PCR analysis . The cmpd-26, an analogue of cinanserin, showed an IC 50 of 1.06 μM for SARS-CoV Mpro (Yang et al., 2008) . inhibition in viral yield. The conclusion is that a "cocktail" of antiviral drugs may reduce compound concentrations and increase inhibition of viral replication (Choy et al., 2020) .

Finally, chloroquine and hydroxychloroquine both inhibit SARS-CoV-2 in cell assays (EC 50 = 5.47 μM vs 0.7 μM in the Vero cell infection model, respectively) (Yao et al., 2020) , though displaying suboptimal affinity scores of −5.0 kcal/mol and −5.9 kcal/mol, respectively (Huynh et al., 2020) .

The lack of information pertaining PLpro, as compared with Mpro, in particular its mechanism of action and involvement in viral replication, does not rule out the possibility that it represents an excellent candidate for drug screening. In this respect, two substrates with natural and unnatural amino acids (i.e., Ac-hTyr-Dap-Gly-Gly-ACC and Ac-Abu(Bth)-Dap-Gly-Gly-ACC) were converted into inhibitors by exchanging the fluorescent tag (7- 

In the last months, some of the drugs and compounds reported previously were employed in the (Guzik et al., 2020) . Two other anti-HIV protease inhibitors, known to potentially inhibit SARS-CoV-2 Mpro (Liu et al 2020c) , were employed in clinical trials, namely lopinavir and ritonavir, which were administered in adults hospitalized with severe COVID-19. Lopinavir efficacy was modest and detected only in the early phase of SARS-CoV-2 infection, discouraging its use at the later stage of viral infection; further, lopinavir/ritonavir showed side-effects, such as nausea, diarrhoea and hepatotoxicity (Cao et al., 2020) . However, since infants and young children had relatively more severe illness than older children, a trial of hydroxychloroquine or lopinavir/ritonavir suggested their use in severe pneumonia and critically ill children (Sankar et al., 2020) .

The chloroquine and hydroxychloroquine, originally employed for malaria treatment, deserve a further clarification, since they should block the SARS-CoV-2 viral entry into cells by elevation of endosomal pH and by inhibition the terminal glycosylation of ACE2 (Vincent et al 2005) , thus ultimately interfering with virus receptor binding. Unfortunately, the clinical data and the effect of hydroxychloroquine in combination with azithromycin are mostly controversial about their efficacy in COVID-19 treatment. Hydroxychloroquine and chloroquine have certain limitations and toxicity, especially on the heart and eyes. Considering their ocular, cardiac and neuro toxicities, hydroxychloroquine and chloroquine should not be recommended as preventive drugs for the COVID-19 pandemic (Zou et al 2020) . A larger, randomized, placebo trial with a prolonged followup will be required in the near future (Shih et al., 2020) .

Remdesivir is a nucleotide analogue prodrug that inhibits RNA-dependent RNA-polymerase, but it is not a Mpro protease inhibitor and only in a computational study it was suggested that may be an inhibitor of both proteins (Huynh et al., 2020) . However, a clinical study about the compassionate use of remdesivir for patients with severe COVID-19 revealed a clinical improvement in 36 of 53 patients (68%), even though a placebo-controlled trial will be required (Grein et al., 2020) . In a second study, the remdesivir was not associated with statistically significant clinical benefits in adult patients with severe COVID-19, but a larger study will be required to confirm the data .

In a non-randomized study of 67 patients, affected by COVID-19, a lower mortality rate was shown to occur in patients treated with umifenovir (arbidol hydrochloride), as compared with patients who did not receive the drug (Shih et al., 2020) . Moreover, in a small group of patients without invasive ventilation, an interesting study showed that oral arbidol plus lopinavir/ritonavir was associated with a significant negative conversion rate of coronavirus test in 7-day and 14-day, with respect to the lopinavir/ritonavir therapy group . Umifenovir is not a protease inhibitor itself and inhibits membrane fusion of the viral envelope by targeting the interaction of the S protein with ACE2.

Favipiravir, an anti-influenza drug approved in Japan, interferes with viral replication and it is a potential inhibitor of RNA-dependent RNA-polymerase. A randomized study, conducted in a Chinese medical centre, compared umifenovir (200 mg*3/day) and favipiravir (1600 mg*2/first day followed by 600 mg*2/day) showing that, unlike umifenovir, favipiravir did not significantly improve the clinically recovery rate at Day 7 (Shih et al., 2020) .

In spite of a great effort worldwide, current drugs have only a limited efficacy in treating COVID-19;

on the other hand, given the high rate of infectivity of SARS-CoV-2 with diffuse lethal effects, especially in immunocompromised patients, the design of new drugs targeting specific activities of the virus and its infection cycle is essential (Hasan et al. 2020) .

Considerable progress has been made in the field of the peptide-based drug design using peptidomimetics, including the development of novel chemical strategies to improve the biological activity, specificity and stability of peptides. These advances turn into new realistic options whenever peptides can be transformed from lead compounds to 'druggable' molecules with improved power and stability profiles. Combined with novel delivery technologies, peptide-based drugs can be addressed to specific cellular targets, thus avoiding other cells expressing the same targets. These two major elements can now be added to the already known favourable properties of peptide-based drugs, such as their high biological activity, specificity, low toxicity, biodegradability and minimal potential for drug interactions.

The emergence of resistant strains under drug selective pressure and their limited availability in high-risk cases further exacerbates the need for new therapeutic strategies. The most obvious target is the virus cycle, trying to stop one of steps in this vicious cycle; in this respect, many laboratories have focussed on inhibitors of the main protease MPro and/or the PLpro. However, since the cycle occurs inside the host cell, this approach demands a deep investigation on the biological molecular mechanisms of SARS-CoV-2, requiring the virus isolation in vitro and its cultivation, as it is usually employed to verify the proof of principle of the viral infection process. However, it may not usually be practical, demanding particular facilities that are not easily accessible in bioresearch laboratories.

Another possible approach to explore the SARS-CoV-2 life cycle is to clone a protein gene P into an appropriate vector, transfect the cells, incubate them with the related protease, purify the protein and carry out the protein assays. This approach shows a number of drawbacks, such as the need of the viral genome, expensive synthesizing processes, availability of monoclonal antibodies, and timeconsuming process (Jaimes et al. 2020a ).

An approach more realistic for laboratories and "a simple to undertake" method is to focus on host proteases involved in the entry of the viral genome. Thus, exploring the cellular factors, An additional aspect is that targeting host proteases, such as furin, TMPRSS2 and/or cathepsins, leads to the production of more "all-purpose" drugs, which are not SARS-Cov2 -specific, but they instead may interfere with enveloped-virus entry mechanism, which is common (at least in general terms) to several viruses; therefore, given the growing probability of forthcoming pandemics in the next future, host specific drugs are likely going to be more effective and of more widespread use.

In any case, the lesson, which emerges from this pandemic situation, is that drugs treatment and new studies about SARS-CoV-2 macromolecular targets are extremely important for limiting the effects of future pandemics, but the vaccine will be absolutely necessary to avoid the virus diffusion at its root. Actually, several ongoing clinical trials vaccines are in phase II and III, being based on different biotechnological platforms. The hope is that the solution with a large vaccination campaign of the world population will take place in the early months of 2021. replication amplifies the number of virus genome copies (7). The viral genome produces pps, which help to take command over host ribosomes for their own translation process; protein biosynthesis starts at the endoplasmic reticulum (ER) and follows the constitutive secretory pathway along Golgi compartments (8). The virion assembly occurs (9) and the newly packed viral particles can egress (10). (HR1/2), and the transmembrane domain (TM).The region between the two domain is termed S1/S2

site. (C): Sequence of S1/S2 cleavage site of S protein from SARS-CoV-2. The four amino acid insertion (SPRRs), unique to SARS-CoV-2, is marked in yellow, the conserved S1/S2 cleavage site is marked in grey. (D): Comparative sequences of S protein cleavage sites. (Henrich et al., 2003) . Furin is shown in light blue. The inhibitor is displayed in black sticks with nitrogen in blue and oxygen in red. The figures of panels B and C were drawn using the UCSF Chimera software (Pettersen et al., 2004) . For details, see the text. . The catalytic triad (i.e.,

His296, Asp345, Ser441) and the predicted interactions of camostat with the active site residues (i.e.,

Asp187, Asn346, Cys348, and Asn450) of the human serine protease are shown. TMPRSS2 is shown in tan. The inhibitor is displayed in black sticks with nitrogen in blue, and oxygen in red. The figures of panels B and C were drawn using the UCSF Chimera software (Pettersen et al., 2004) . For details, see the text.

Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV

Emerging Coronaviruses: genome structure, replication, and pathogenesis

The primary structure and expression of the second open reading frame of the polymerase gene of the coronavirus MHV-A59: a highly conserved polymerase is expressed by an efficient ribosomal frameshifting mechanism

The complete sequence (22 kilobases) of murine coronavirus gene 1 encoding the putative proteases and RNA polymerase

Proteolytic activation of the SARS-Coronavirus Spike protein: cutting enzymes at the cutting edge of antiviral research

Handbook of proteolytic enzymes

Human matrix metalloproteinases: an ubiquitarian class of enzymes involved in several pathological processes

Structure of the SARS-CoV-2 Spike receptor-binding domain bound to the ACE2 receptor

Priming time: how cellular proteases arm Coronavirus Spike proteins activation of viruses by host Proteases

Characterization of proproteins converted and their involvement in the spread of the virus

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

Wild-type human coronaviruses prefer cell-surface TMPRSS2 to endosomal cathepsins for cell entry

The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade

Furin at the cutting edge: from protein traffic to embryogenesis and disease

Böttcher-Friebertshäuser, TMPRSS2 and furin are both essential for proteolytic activation and spread of SARS-CoV-2 in human airway epithelial cells and provide promising drug targets

Significant expression of FURIN and ACE2 on oral epithelial cells may facilitate the efficiency of 2019-nCov entry

Profile of a killer: the complex biology powering the coronavirus pandemic

A pneumonia outbreak associated with a new coronavirus of probable bat origin

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Nafamostat mesylate blocks acrivation of SARS-CoV-2: new treatment option for COVID-19

Phylogenetic analysis and structural modeling of SARS-CoV-2 Spike protein reveals an evolutionary distinct and proteolytically sensitive activation loop

Prostatelocalized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2

Cloning and characterization of the cDNA and gene for human epitheliasin

From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design

Structure, function, and antigenicity of the SARS-CoV-2 Spike glycoprotein

Structure analysis of the receptor binding of 2019-nCoV

Proteolytic cleavage of the SARS-CoV-2 Spike protein and the role of the novel S1/S2 Site

Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target

The proximal origin of SARS-CoV-2

Mechanisms of the cellular entry of the coronavirus mediated by the viral protein of the peak virus. Viruses

Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites

Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein

Cryo-EM structure of the 2019-nCoV Spike in the prefusion conformation

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

CD147 as a target for COVID-19 treatment: suggested effects of Azithromycin and stem cell engagement

SARS-Cov-2 spike S1 receptor binding domain undergoes conformational change upon interaction with low molecular weight heparins

Tissue distribution of ACE2 protein, the functional receptor for SARS Coronavirus. A first step in understanding SARS pathogenesis

Inhibition of HIV-1 gp160-dependent membrane fusion by a furin-directed α1-antitrypsin variant

The structure of the unliganded form of the proprotein convertase furin suggests activation by a substrate-induced mechanism

X-ray structures of proprotein convertase furin bound with substrate analogue inhibitors reveal substrate specificity determinants beyond the S4 pocket

Novel furin inhibitors with potent anti-infectious activity

Probable origin of the SARS-CoV-2 pangolin associated with the COVID-19 outbreak

Inhibition of furinmediated cleavage activation of HIV-1 glycoprotein gp160

Therapeutic uses of furin and its inhibitors: a patent review

Engineered serine protease inhibitor prevents Furin-catalyzed activation of the fusion glycoprotein and production of infectious measles virus

Serpin-like properties of alpha1-antitrypsin Portland towards Furin convertase

Targeting host proteinases as a therapeutic strategy against viral and bacterial pathogens

Polyarginines are potent Furin inhibitors

Synthetic small molecule furin inhibitors derived from 2,5-dideoxystreptamine

Structural studies revealed active site distortions of human Furin by a small molecule inhibitor

Furin-mediated protein processing in infectious diseases and cancer

The crystal structure of the proprotein processing proteinase Furin explains its stringent specificity

Inhibition of proteolytic activation of influenza virus hemagglutinin by specific peptidyl chloroalkyl ketones

Therapeutic potential of furin inhibitors for the chronic infection of hepatitis B virus

Inhibition of Chikungunya virus infection in cultured human muscle cells by furin inhibitors: impairment of the maturation of the E2 surface glycoprotein

The role of furin in papillomavirus infection

Decanoyl-Arg-Val-Lys-Arg-Chloromethylketone: an antiviral compound that acts against Flaviviruses through the inhibition of furin-mediated prM cleavage

Pöhlmann Inhibition of proprotein convertases abrogates processing of the middle eastern respiratory syndrome coronavirus spike protein in infected cells but does not reduce viral infectivity

A multibasic cleavage site in the Spike protein of SARS-CoV-2 is essential for infection of human lung, Cells

Potent inhibitors of Furin and Furin-like proprotein convertases containing decarboxylated P1 arginine mimetics

Elongated and Shortened Peptidomimetic Inhibitors of the Proprotein Convertase Furin

Design, synthesis, and characterization of macrocyclic inhibitors of the proprotein convertase Furin

The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis

Androgen receptor and androgendependent gene expression in lung

TMPRSS2: a potential target for treatment of influenza virus and coronavirus infections

Potential effects of coronaviruses on the cardiovascular system: a review

Potential biomarker for COVID-19 outcomes

Identification of a potential mechanism of acute kidney injury during the COVID-19 outbreak: a study based on single-cell transcriptome analysis

Influenza and SARS coronavirus activating proteases TMPRSS2 and HAT are expressed at multiple sites in human respiratory and gastrointestinal tracts

TMPRSS2 and COVID-19: serendipity or opportunity for intervention? Cancer Discov

Cloning of the TMPRSS2 gene, which encodes a novel serine protease with transmembrane, LDLRA and SRCR domains and maps to 21q22

TMPRSS2 (transmembrane protease, serine 2)

Type II transmembrane serine proteases

Membrane-anchored serine proteases in health and disease

Structural basis of SARS-CoV-2 Spike protein priming by TMPRSS2

Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers

Structural comparison strengthens the higher order classification of proteases related to chymotrypsin

Demonstration of the acyl-enzyme mechanism for the hydrolysis of peptides and anilides by chymotrypsin

Proteolytic activation of influenza viruses by serine proteases TMPRSS2 and HAT from human airway epithelium

Cleavage of influenza virus hemagglutinin by airway proteases TMPRSS2 and HAT differs in subcellular localization and susceptibility to protease inhibitors

Proteolytic activation of the 1918 influenza virus Hemagglutinin

Efficient activation of the severe acute respiratory syndrome coronavirus Spike protein by the transmembrane protease TMPRSS2

Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry

TMPRSS2 is essential for influenza H1N1 virus pathogenesis in mice

TMPRSS2 is a host factor that is essential for pneumotropism and pathogenicity of H7N9 influenza A virus in mice

The host protease TMPRSS2 plays a major role in in vivo replication of emerging H7N9 and seasonal influenza viruses

TMPRSS2 contributes to virus spread and immunopathology in the airways of murine models after coronavirus infection

Protease inhibitors targeting coronavirus and filovirus entry

Virtual screening of natural products against type II transmembrane serine protease (TMPRSS2), the priming agent of Coronavirus 2 (SARS-CoV-2)

Alpha 1 antitrypsin is an inhibitor of the SARS-CoV-2 priming protease

Homology modeling and docking studies of TMPRSS2 with experimentally known inhibitors Camostat mesylate, Nafamostat and Bromhexine hydrochloride to control SARS-Coronavirus-2

Acute-pahse protein alpha-1 antitrypsin: diverting injurious innate and adaptive immune responses from non-authentic threats

The interaction of human tryptasebeta with small molecule inhibitors provides new insights into the unusual functional instability and quaternary structure of the protease

Coronavirus cell entry occurs through the endo-/lysosomal pathway in a proteolysis-dependent manner

5-Lipoxygenase inhibitors isolated from Gardeniae fructus

Direct inhibition of TLR4/MyD88 pathway by geniposide suppresses HIF1-independent VEGF expression and hepatocellular carcinoma angiogenesis

Geniposide attenuates post-ischaemic neurovascular damage via GluN2A/AKT/ERK-dependent mechanism

Failure of ventral closure and axial rotation in embryos lacking the proprotein convertase Furin

Reverse genetics demonstrates that proteolytic processing of the Ebola virus glycoprotein is not essential for replication in cell culture

Pathway for polyarginine entry into mammalian cells

Proprotein convertase inhibition: paralyzing the cell's master switches

Targeting proprotein convertases in furin-rich lung cancer cells results in decreased in vitro and in vivo growth

A review on the phytochemistry, pharmacology, pharmacokinetics and toxicology of geniposide, a natural product

Protease inhibitors: candidate drugs to inhibit severe acute respiratory syndrome Coronavirus 2 replication

S-nitrosylation of viral proteins: molecular bases for antiviral effect of nitric oxide

Inhaled NO and COVID-19

Inferring the hosts of coronavirus using dual statistical models based on nucleotide composition

Structural and evolutionary analysis indicate that the SARS-CoV-2 Mpro is a challenging target for smallmolecule inhibitor design

The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved αketoamide inhibitors

Structural basis of inhibition specificities of 3C and 3C-like proteases by zinc-coordinating and peptidomimetic compounds

The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds

Virus-encoded proteinases and proteolytic processing in the Nidovirales

Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra alpha-helical domain

pH-dependent conformational flexibility of the SARS-CoV main proteinase (M(pro)) dimer: molecular dynamics simulations and multiple X-ray structure analyses

Insight into the activity of SARS main protease: Molecular dynamics study of dimeric and monomeric form of enzyme

Mutational analysis of the active centre of coronavirus 3C-like proteases

Drug binding dynamics of the dimeric SARS-CoV-2 main protease determined by molecular dynamics simulation

Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs

Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV

Activity profiling and structures of inhibitor-bound SARS-CoV-2-PLpro protease provides a framework for anti-COVID-19 drug design

Dimerization of HIV-1 protease occurs through two steps relating to the mechanism of protease dimerization inhibition by darunavir

Structure of M pro from SARS-CoV-2 and discovery of its inhibitors

Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease

Discovery of a novel family of SARS-CoV protease inhibitors by virtual screening and 3D-QSAR studies

Investigation of some antiviral Nheterocycles as COVID 19 drug: molecular docking and DFT calculations

Interaction of the prototypical α-ketoamide inhibitor with the SARS-CoV-2 main protease active site in silico: molecular dynamic simulations highlight the stability of the ligand-protein complex

Hilgenfeld, α-Ketoamides as broad-spectrum inhibitors of Coronavirus and Enterovirus replication: structure-based design, synthesis, and activity assessment

A molecular modeling approach to identify effective antiviral phytochemicals against the main protease of SARS-CoV-2

Potential inhibitors for novel Coronavirus protease identified by virtual screening of 606 million compounds

Identification of potential natural inhibitors of SARS-CoV2 main protease by molecular docking and simulation studies

Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 Mpro enzyme through in silico approach

Identification of phytochemical inhibitors against main protease of COVID-19 using molecular modeling approaches

Withanone and caffeic acid phenethyl ester are predicted to interact with main protease (Mpro) of SARS-CoV-2 and inhibit its activity

Identification of bioactive molecules from tea plant as SARS-CoV-2 main protease inhibitors

Identification of new anti-nCoV drug chemical compounds from Indian spices exploiting SARS-CoV-2 main protease as target

Andrographolide as a potential inhibitor of SARS-CoV-2 main protease: an in silico approach

Hispidin and Lepidine E: two natural compounds and Folic acid as potential inhibitors of 2019-novel coronavirus main protease (2019-nCoVMpro), molecular docking and SAR study

Marine natural compounds as potents inhibitors against the main protease of SARS-CoV-2-a molecular dynamic study

Putative inhibitors of SARS-CoV-2 main protease from a library of marine natural products: a virtual screening and molecular modeling study

Prediction of novel inhibitors of the main protease (M-pro) of SARS-CoV-2 through consensus docking and drug reposition

Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: possible implication in COVID-19 therapy

Molecular investigation of SARS-CoV-2 proteins and their interactions with antiviral drugs

Using integrated computational approaches to identify safe and rapid treatment for SARS-CoV-2

An investigation into the identification of potential inhibitors of SARS-CoV-2 main protease using molecular docking study

Triazavirin -potential inhibitor for 2019-nCoV Coronavirus M protease: a DFT study

Potential anti-viral activity of approved repurposed drug against main protease of SARS-CoV-2: an in silico based approach

Statins and the COVID-19 main protease: in silico evidence on direct interaction

Identification of potential molecules against COVID-19 main protease through structure-guided virtual screening approach

Potential anti-SARS-CoV-2 drug candidates identified through virtual screening of the ChEMBL database for compounds that target the main coronavirus protease

Drug repurposing for coronavirus (COVID-19): in silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes

In silico exploration of the molecular mechanism of clinically oriented drugs for possibly inhibiting SARS-CoV-2's main protease

Discovery of baicalin and baicalein as novel, natural product inhibitors of SARS-CoV-2 3CL protease in vitro

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease

Discovery of M Protease Inhibitors Encoded by SARS-CoV-2

FEP-based screening prompts drug repositioning against COVID-19

Design and synthesis of cinanserin analogs as severe acute respiratory syndrome coronavirus 3CL protease inhibitors

Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro

Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Characterization and noncovalent inhibition of the deubiquitinase and deISGylase activity of SARS-CoV-2 papain-like protease

X-ray structural and biological evaluation of a series of potent and highly selective inhibitors of human coronavirus papain-like proteases

COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options

Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines

A trial of Lopinavir-Ritonavir in adults hospitalized with severe Covid-19

COVID-19 in children: clinical approach and management

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread

Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVI19

Fighting COVID-19: a quick review of diagnoses, therapies, and vaccines

Compassionate use of Remdesivir for patients with severe Covid-19

Arbidol combined with LPV/r versus LPV/r alone against Coronavirus disease 2019: q retrospective cohort study

A review on the cleavage priming of the spike protein on coronavirus by angiotensin-converting enzyme-2 and furin

Use of furin and furin-like protease inhibitors in the treatment of inflammatory or matrix remodelling diseases patent

Selective and potent furin inhibitors protect cells from anthrax without significant toxicity

UCSF Chimera--a visualization system for exploratory research and analysis

Analysis of sequence and structure of Mpro (3CL) protease. (A): Multi-alignment of Mpro homologues from the seven known human coronaviruses: SARS-CoV-2 (Uniprot ID: P0DTD1)

HCoV-229E (P0C6U2)

The structural domains I, II and III of Mpro are colored in light blue, orange and green, respectively. The localization of the protease active site (i.e., residues Cys41 and His145) and the "N-finger" are indicated by arrows. (C): SARS-CoV-2 Mpro complexed with N3 peptide (PDB: 6LU7). Mpro structure is represented by molecular surface colored with the same scheme used in panel B

Ligands docked in Mpro active site. Examples of ligands docked in the active site

This review availed very much of fruitful discussions with several colleagues, namely Profs. R. 

Eszopiclone. Ligands were docked using Autodock Vina with the protocol developed elsewhere (Calligari et al., 2020) . The structural domains I, II and III of Mpro are colored in light blue, orange and green, respectively. Limits joint inflammation when delivered with adenovirus into the joint of arthritic mice. Anderson et al., 1993 Thomas et al., 1994 Watanabe et al., 1995 Dubois et al., 2004 Dec-Arg-Val-Lys-Arg-CMK 1000 Topical uses in the treatment of HPV skin infections.Antiviral activity against HIV, Chikungunya virus, ZIKV, JEV, chronic HBV, influenza A, and EVD, in cell models.Inhibits processing of MERS-S protein in infected cells.Block SARS-CoV-2-S processing in rhabdoviral particles .